Triplet Therapeutics to Present at Upcoming Events - Mar 25, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced that Nessan Bermingham, Ph.D., Triplet’s chief executive officer, president and founder, will present at the following upcoming virtual events:

• Stifel 2021 CNS Day, Thursday, April 1, 2021 fireside chat at 2:00 p.m. ET;
• Guggenheim Healthcare Talks 2021 | Genomic Medicines & Rare Disease, Thursday, April 1, 2021, panel: “An idea whose time has come – disease modifying therapies for Huntington’s disease,” at 3:00 – 3:50 p.m. ET.

Dr. Bermingham will discuss Triplet’s recent activities, including plans to file an investigational new drug application for TTX-3360 in Huntington’s disease in the second half of 2021, pipeline development and completion of enrollment of SHIELD HD, its natural history study of Huntington’s disease.

About Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) – a group of more than 50 known genetic diseases including Huntington’s disease (HD), myotonic dystrophy type 1 (DM1), spinocerebellar ataxias (SCAs), fragile X syndrome and familial amyotrophic lateral sclerosis (ALS) – leveraging insights from patient genetics. Triplet uses a proprietary approach to design, develop and deliver potential therapeutics for REDs, enabling the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs.

Triplet is headquartered in Cambridge, Mass. For more information, please visit www.triplettx.com.

About TTX-3360
TTX-3360, an antisense oligonucleotide, is Triplet’s first clinical candidate. TTX-3360 is the first clinical candidate with the potential to modify the course of REDs, including HD, by targeting the DDR pathway. Triplet plans to file an investigational new drug application for TTX-3360 in the second half of 2021, with a focus on HD. TTX-3360 may also be a candidate for the treatment of other central nervous system diseases including SCAs, DM1 and approximately 30 additional potential REDs impacting the central nervous system.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210325005131/en/